Central Connecticut Neurosurgery and Spine is the First in Connecticut to Offer New Treatment Option for Chronic Pain

PLANO, TEXAS (PRWEB) MAY 17, 2017

Dr. Ahmed Khan is the first physician in Connecticut to implant Nuvectra’s Algovita® Spinal Cord Stimulation System, a powerfully versatile, patient-centric spinal cord stimulation system. The Algovita SCS System has been FDA approved as a treatment option for chronic intractable pain since late last year.

Chronic pain affects over 100 million Americans, according to the Institute of Medicine, more than diabetes, cancer, and heart disease combined. Chronic pain is difficult to treat, but one potential treatment option is spinal cord stimulation, or SCS. SCS works by masking or interrupting pain signals as they travel up the spinal cord to the brain. A small, rechargeable battery is implanted under the patient’s skin and connected to thin wires, called leads, which stimulate the nerves sending pain signals. The stimulation “overrides” the pain signals, and instead of feeling pain, patients may feel a tingling sensation known as paresthesia.

The Algovita SCS System is a new offering to the SCS market, featuring 24 current sources and the broadest overall set of parametric ranges offered for tonic SCS. This combination provides flexible coverage and expanded programming options for individualized patient therapy. Algovita also offers the industry’s only stretchable leads, which are designed to reduce the risk of lead fracture and migration. In addition, the system’s percutaneous leads feature up to 12 contacts for wide coverage of potential pain areas. The Algovita system was designed to be patient-centric and easy to use. The wireless Pocket Programmer fits discreetly in a hand, purse, or pocket and allows a patient to conveniently adjust their therapy on the go.

For more information about Nuvectra and the Algovita Spinal Cord Stimulation system, visit http://www.nuvectramed.com.

About Dr. Ahmed Khan

Dr. Ahmed Khan is a neurosurgeon in New Britain, Connecticut and is affiliated with Bristol Hospital. He received his medical degree from University of Connecticut School of Medicine and has been in practice for more than 20 years. He is one of 2 doctors at Bristol Hospital who specialize in Neurological Surgery.

About Nuvectra Corporation

NuvectraTM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at http://www.nuvectramed.com.